PSTV Company Profile and Key Details

PSTV has shown weak momentum, losing -41.8% over the past week and -54.0% over the past quarter, though year-to-date performance is down -44.33%. Short-term trend indicators are bullishly aligned (SMA20 21.9%, SMA50 -15.99%, SMA200 -31.13%). The stock’s 14-day RSI is 54.77 (neutral), while the ATR of 0.03 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -85.96% below its high and over 98.47% above its low. Average 10-day trading volume of 191.70 thousand shares is in line with the 3-month average of 178.53 thousand, indicating normal recent market interest.

Plus Therapeutics, Inc. (NASDAQ:PSTV) closed at $3.80 USD, losing -$0.12 (-3.06%) from the previous close of $3.92. The stock is currently mid-range between its 52-week high and low $2.90 and $23.50. With a market capitalization of about $9.19 million, Plus Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.40). Key stats such as the average daily volume over the past year has been around 173.91 thousand shares, volume is running light vs its 52-week average. Headquartered in Austin, TX, Plus Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Marc H. Hedrick, the company employs approximately 28 people and listed since July 11, 2001. Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, dedicated to the development, manufacturing, and market introduction of therapeutic solutions for cancer patients and individuals with other serious illnesses.

Plus Therapeutics, Inc. has 99.26 million shares outstanding. The public float is 99.06 million shares, elevated short interest at 3.15% of float. This equals 3.12 million shares. The short ratio is 0.17 days. Institutional investors hold 10.42% of the float. Insiders own 1.84%. Lim Kian Thiam holds 7.40 million shares, Swissquote Bank SA has 5.33 million shares and PostFinance AG has 4.54 million shares.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Plus Therapeutics, Inc. generated EPS of -$1.90 over the past year. Five-year average earnings growth is 46.51%. Wall Street analysts project EPS growth of 66.24% annually over the next five years. The latest quarter delivered EPS of -$1.05. The next quarter is forecast at -$0.03. Next year's EPS is expected at $58.28. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 19 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $65.00 to $1.00. The high target offers 1558.16% upside. The low target suggests -74.49% downside. The mean target is $11.84. This offers 202.04% upside. Plus Therapeutics, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 15, 2026, missed forecasts by 23.82%. The prior quarter beat by 4.2%. Over the last six quarters, Apple has recorded several small beats. These include 31.37% in March 27, 2025.

Plus Therapeutics, Inc. trades at a P/E ratio of -0.01, slightly below the S&P 500 average, with a price-to-sales ratio of 1.84 and a price-to-book ratio of 2.19 suggesting the stock is closer to book value. The P/FCF stands at -0.44, also above market averages.

Plus Therapeutics, Inc. (NASDAQ:PSTV) shares are down -44.33% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Plus Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.01. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $10.12, suggesting 158.16% upside. Our AI forecast model points to short-term weakness (-4.85% over two weeks), a medium-term rise (246.43% over three months), and a longer-term loss (-96.43% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Plus Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.85%, with price expected at $3.73 by August 04, 2026, within a range of $3.48 to $3.99 3-Month Outlook: Projected rise of 246.43%, reaching $13.58 by October 19, 2026, with a range of $12.38 to $15.33. 1-Year Outlook: Projected loss of -96.43%, with price at $0.14 by July 21, 2027, within a range of $0.00 to $1.28.